Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Allogene Therapeutics, Inc. (ALLO)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Allogene Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Allogene Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is ALLO. The reporting company's CIK number is 1737287.
The total value of stock buying since 2005 is $15,310,008.
The total value of stock sales since 2005 is $56,373,021.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2019-05-14||Coulter James G||Sale||1,918,755||29.38||56,373,021|
|2018-10-15||Witte Owen N. (Director)||Buy||15,000||18.00||270,000|
|2018-10-15||Chang David D (President and CEO)||Buy||40,000||18.00||720,000|
|2018-10-15||Humer Franz B (Director)||Buy||30,000||18.00||540,000|
|2018-10-15||Belldegrun Arie (Director)||Buy||35,000||18.00||630,000|
|2018-10-15||Coulter James G||Buy||675,000||18.00||12,150,000|
|2018-10-15||Pfizer Inc (10% Owner)||Buy||55,556||18.00||1,000,008|
Insider trading activities including stock purchases, stock sales, and option exercises of ALLO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Allogene Therapeutics, Inc. (symbol ALLO, CIK number 1737287) see the Securities and Exchange Commission (SEC) website.